Hua Medicine-B (02552) to Review FY2025 Results and Final Dividend Proposal on 26 March 2026

Bulletin Express

Mar 16

Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026.

The agenda includes: 1. Approval of the audited financial results for the year ended 31 December 2025. 2. Consideration of a final dividend recommendation, if any. 3. Discussion of other routine corporate matters.

The board currently consists of three executive directors (Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang), one non-executive director (Mr. Robert Taylor Nelsen) and three independent non-executive directors (Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung).

The company will release its FY2025 results after board approval, providing shareholders with detailed financial information and any dividend decision.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1185329206"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185329206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185329206?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185329206","market":"us","top_or_hot":-1,"title":"Hua Medicine-B (02552) to Review FY2025 Results and Final Dividend Proposal on 26 March 2026","media":"Bulletin Express","content":"<p>Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026.</p>\n<p>The agenda includes:\n1. Approval of the audited financial results for the year ended 31 December 2025.\n2. Consideration of a final dividend recommendation, if any.\n3. Discussion of other routine corporate matters.</p>\n<p>The board currently consists of three executive directors (Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang), one non-executive director (Mr. Robert Taylor Nelsen) and three independent non-executive directors (Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung).</p>\n<p>The company will release its FY2025 results after board approval, providing shareholders with detailed financial information and any dividend decision.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hua Medicine-B (02552) to Review FY2025 Results and Final Dividend Proposal on 26 March 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHua Medicine-B (02552) to Review FY2025 Results and Final Dividend Proposal on 26 March 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-16 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026.</p>\n<p>The agenda includes:\n1. Approval of the audited financial results for the year ended 31 December 2025.\n2. Consideration of a final dividend recommendation, if any.\n3. Discussion of other routine corporate matters.</p>\n<p>The board currently consists of three executive directors (Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang), one non-executive director (Mr. Robert Taylor Nelsen) and three independent non-executive directors (Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung).</p>\n<p>The company will release its FY2025 results after board approval, providing shareholders with detailed financial information and any dividend decision.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02552","symbol_name":"华领医药-B","start_time":0,"source_url":"","article_id":"1185329206","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185329206","pubTimestamp":1773650435,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026. The agenda...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02552":"华领医药-B"},"translate_title":"华领医药-B(02552)将于2026年3月26日审阅2025财年业绩及末期股息建议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02552":1},"content_text":"Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026.\nThe agenda includes:\n1. Approval of the audited financial results for the year ended 31 December 2025.\n2. Consideration of a final dividend recommendation, if any.\n3. Discussion of other routine corporate matters.\nThe board currently consists of three executive directors (Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang), one non-executive director (Mr. Robert Taylor Nelsen) and three independent non-executive directors (Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung).\nThe company will release its FY2025 results after board approval, providing shareholders with detailed financial information and any dividend decision.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}